Sleeve gastrectomy (SG) has become the most commonly performed weight loss surgery, accounting for 60% of all bariatric operations worldwide. While technically easier with less side-effects and nutritional risks than other operations, SG is also associated with a higher risk of failure (20 to 40%). In such case, the most effective option consists in adding an intestinal bypass called the Biliopancreatic Diversion with Duodenal Switch (BPD-DS). This surgery is, however, technically challenging and yields a significant risk of complications, nutritional deficiencies or gastro-intestinal side-effects. Recently, a simplified version of the Standard DS, called Single-Anastomosis Duodenoileal Switch (SADI-S) was endorsed by surgical societies as one of the approved bariatric procedures. There is currently no prospective or randomized data to support the effectiveness of this new procedure, especially as a revisional approach. The Overall Objective of this randomized controlled trial project is to establish the clinical benefits of the SADI-S as a revisional surgery after SG, while also considering critical issues related to sex and gender. The investigator Overall Hypothesis is that the SADI-S represents a relevant revisional option for weight loss and metabolic recovery in women and men suffering from severe obesity who had a previous SG. The investigator propose to address the following research question. Research Question: What are the clinical effects of SADI-S compared to standard DS when used as a revisional procedure after SG, in patients with obesity? Participants who need revisional surgery after SG will be enrolled in a prospective, randomized, double-blind (patient-evaluator), non-inferiority trial comparing SADI-S vs DS. The primary outcome will be 12-month excess weight loss. Secondary outcomes will be perioperative complications, risk of malnutrition, quality of life and gastrointestinal side effects. The investigator hypothesize that SADI-S offers similar weight loss compared to standard DS, but a lower risk of complications and nutritional deficiencies. With the increase in the number of bariatric operations performed worldwide and the recent endorsement of the SADI-S as a regular procedure, reliable clinical data are urgently needed. The present proposal will directly address this knowledge gap.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
151
Standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)
Single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)
Institut Universitaire de Cardiologie et de Pneumologie de Québec
Québec, Quebec, Canada
RECRUITINGExcess weight loss
Percentage of excess weight loss mobilized in response to surgery
Time frame: 12 month
Peroperative complications
Complications graded with Clavien classification
Time frame: from baseline up to 60 months
Risk of malnutrition
Risk of malnutrition assessed through measurement of its risk being mild (albumin\<35g\\L), moderate (albumin\<30g/L) or severe (albumin\<25g/L)
Time frame: from baseline to 60 months
Change in quality of life (SF-36)
36-item short form survey evaluating quality of life on a scale form 0 to 100
Time frame: from baseline to 60 months
Change in quality of life (BAROS)
Bariatric Analyses and Reporting Outcomes System score form -7 to 9
Time frame: from baseline to 60 months
Change in quality of life (QLaval)
Laval questionnaire evaluating quality of life on 6 aspects on a scale from 0 to 7
Time frame: from baseline to 60 months
Gastro-intestinal side effects
Evaluation of gastro-intestinal side effects with the Gastro-Intestinal Quality of Life Index from 0 to 144
Time frame: from baseline to 60 months
Change in nutritional status (calcium)
Change in nutritional status based on blood analysis of calcium (mmol/L)
Time frame: from baseline to 60 months
Change in nutritional status (ferritin)
Change in nutritional status based on blood analysis of ferritin (ug/L)
Time frame: from baseline to 60 months
Change in nutritional status (TIBC)
Change in nutritional status based on blood analysis of TIBC (umol/L)
Time frame: from baseline to 60 months
Change in nutritional status (iron)
Change in nutritional status based on blood analysis of iron (umol/L)
Time frame: from baseline to 60 months
Change in nutritional status (prealbumin)
Change in nutritional status based on blood analysis of prealbumin (g/L)
Time frame: from baseline to 60 months
Change in nutritional status (transferrin)
Change in nutritional status based on blood analysis transferrin (g/L)
Time frame: from baseline to 60 months
Change in nutritional status (vitamin A)
Change in nutritional status based on blood analysis of vitamin A (umol/L)
Time frame: from baseline to 60 months
Change in nutritional status (vitamin D3)
Change in nutritional status based on blood analysis of vitamin D3 (nmol/L)
Time frame: from baseline to 60 months
Change in nutritional status (parathormone)
Change in nutritional status based on blood analysis parathormone (ng/L)
Time frame: from baseline to 60 months
Change in food intake
Evaluation of the change in food intake using a web-based food frequency questionnaire (kcal/day)
Time frame: from baseline to 60 months
Change in eating behavior
Change of eating behavior using the Three-Factor Eating Questionnaire evaluating cognitive restraint of eating on a scale from 0 to 20, disinhibition on a scale from 0 to 16 and hunger on a scale from 0 to 15
Time frame: from baseline to 60 months
Change in food addiction
Change of eating behavior using the Yale Food Addiction Scale that includes a "symptom count" scale from 0 to 7 reflecting the number of addiction-like criteria endorsed and a dichotomous evaluation that indicates whether a threshold of three or more "symptoms" plus clinically significant impairment or distress has been met
Time frame: from baseline to 60 months
Change in binge eating behavior
Change of eating behavior using the Binge Eating scale from 0 to 46
Time frame: from baseline to 60 months
Evolution of obesity related diseases
Remission rate for comorbidities, including T2D, hypertension, dyslipidemia, sleep apnea according to the ASMBS definition of outcomes reporting
Time frame: from baseline to 60 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.